Hosted by IDTechEx
Truly Global Daily News Interpreted by Experts
HomeEventsReportsTVCareersAbout UsSign-up or LoginIDTechExTwitterLinkedInGoogle+YoutubeRSSForward To Friend
Posted on June 05, 2017

Non-invasive electroceutical for treatment of kidney disease

Printed and Flexible Sensors 2017-2027: Technologi
Endonovo Therapeutics Inc, a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, has announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease. The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
 
"We are excited to start our work on kidney disease and further expand our pipeline of non-invasive therapies targeting vascular diseases and inflammatory conditions in vital organs," commented Endonovo CEO, Alan Collier.
 
The Company's Immunotronics™ platform is a non-invasive electroceutical device that harnesses magnetically-induced electrical field pathways in cells and organs to illicit an anti-inflammatory response in tissues and organs.
 
"Several kidney diseases have a strong inflammatory component and our aim is to demonstrate the anti-inflammatory and anti-fibrotic properties of our non-invasive electroceutical technology. Reversing inflammation in the kidneys that can cause injury, fibrosis and ultimately end-stage renal disease would represent a truly game changing application of bioelectronic medicine," stated Mr. Collier.
 
Webinars Generic Banner
"We not only believe that bioelectronic medicine is the future but that our non-invasive electromagnetic approach will be the standard for treating vital organs," concluded Mr. Collier.
 
About Kidney Disease:
More than 31 million people in the United States are currently living with chronic kidney disease (CKD), according to the American Kidney Fund. Diabetes and high blood pressure are the most common causes of kidney disease.
 
Chronic kidney disease means lasting damage to the kidneys that can get worse over time and in cases where the damage is severe, it can lead to kidney failure, also known as end-stage renal disease. If the kidneys fail the only option for patients is a kidney transplant or dialysis.
 
According to the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), the five-year survival rate for dialysis patients is only 35.8%, in comparison to a five-year survival rate of 85.5% for transplant patients.
 
However, there are currently 100,791 people waiting for a kidney transplant, according to the National Kidney Foundation. This severe donor kidney shortage means that the median wait time for a patient's first kidney transplant is 3.6 years.
 
On average, over 3,000 new patients are added to the kidney waiting list each month and 13 people die each day while waiting for a life-saving kidney transplant.
 
IDTechEx TV add
A significant rise in the pool of patients suffering from CKD, particularly the rising number of elderly people prone to a variety of diseases, such as diabetes, cardiovascular disorders and neurological conditions that affect the kidneys severely will grow the demand for CKD treatments.
 
Source: Endonovo Therapeutics Inc
Top image: Wikimedia
Learn more at the next leading event on the topic: Business and Technology Insight Forum. Korea 2017 External Link on 19 - 21 Sep 2017 in Seoul, Korea hosted by IDTechEx.